Skip to content

As a company committed to therapeutic progress to serve patient needs, Servier takes an open and collaborative approach to R&D at every stage of the drug development life cycle, including early-stage discovery – where we are proud to support the next generation of innovation.

Our awards recognize the aspiring life-science companies and entrepreneurs who are driving scientific innovation in areas of high unmet need, including hard-to-treat diseases in oncology, neuroscience and immuno-inflammation, as well as those pursuing research in translational medicine, drug development technologies and drug delivery platforms.

FAST Discovery Award: California Life Sciences

Servier is a proud FAST Track Partner of the California Life Sciences (CLS) FAST Advisory Program, designed to provide founders of disruptive innovative life science companies with a customized advisory program to perfect their business models, assess strategic focus, maximize IP and help develop a milestone and scale-up plan to exit.

The Servier Discovery Award is open to interested startups developing innovative approaches in oncology, neuroscience and immuno-inflammation; AI/ML data-driven platforms for drug design; and modality development strategies for small molecules, biologics and oligonucleotides, as well as targeted delivery strategies.

The winner of the Servier Discovery Award will be selected to participate in the CLS FAST Fall cohort—a program that matches entrepreneurs with a custom team of advisors for an intensive team review.

Palm Therapeutics was named the winner of the 2023 CLS FAST Discovery Award.

LabCentral Golden Tickets: Cambridge, MA

Servier is a proud Gold sponsor of LabCentral, a premier shared laboratory space located in Cambridge, Massachusetts, designed as a launchpad for life science and biotech startups. Each year, Servier sponsors a contest to award one “Golden Ticket” to support and celebrate promising life-science companies and entrepreneurs. The winner of the “Golden Ticket” will receive a $50,000 credit towards space and services available at LabCentral 700 for use within a 13-month period. Servier will also provide access to its team of talented experts who can provide guidance and feedback to early-stage companies.

2024 Servier Golden Ticket Contest: LabCentral

Servier is pleased to open the call for applications for the 2024 Golden Ticket Contest to interested startups developing innovative approaches in the following discovery and early clinical areas of interest:

  • Innovative therapeutic approaches in:
    • Oncology: Cancer cell targeting (e.g., synthetic lethality, precision oncology) and immuno-oncology (e.g., tumor micro-environment, T-cell targeting)
    • Neuroscience: Rare neurological disorders (e.g., Familial Amyotrophic Lateral Sclerosis, genetically driven pediatric epilepsies) and sub-populations of neurodegenerative diseases
    • Immuno-inflammation: Autoantibody-driven autoimmune diseases and related conditions with similar pathophysiological mechanisms
  • Novel modality development strategies for small molecules, biologics (including bi-specifics, ADCs) and oligonucleotides (including ASOs), as well as targeted delivery strategies (e.g., tumor-specific, CNS delivery mechanisms)
  • AI/ML data-driven platforms for drug design (including oligonucleotides and antibodies) and to support translational activities (target and biomarker identification)

How to Apply:

To apply, submit a non-confidential pitch deck highlighting your innovative approach to advancing therapies for patients with high unmet needs to: All submissions will be reviewed. Four to Five semi-finalists will be invited to a pitch event at LabCentral in Cambridge, MA, where both of the Golden Ticket winners will be announced!


  • Application submission opens February 13, 2024
  • Application deadline March 22, 2024
  • Golden Ticket semi-finalists notified: April 22, 2024
  • Servier Golden Ticket pitch event and announcement of finalist: May 22, 2024


The winner of the “Golden Ticket” Contest shall receive a $50,000 credit towards space and services available at LabCentral 700 for use within a 13-month period, beginning upon receipt. Additional terms and conditions apply, subject to Servier and LabCentral’s discretion. All submissions shall be reviewed. Recipient shall not receive consideration in the form of cash. Recipients seeking access to, and discussions with, Servier employees in the form of guidance or feedback may be required to execute appropriate confidentiality agreements, at Servier’s discretion. If you have any questions, please direct them to

Servier as a Partner-of-Choice

  • Independent, ensuring continuity and long-term perspective in partnerships
  • Committed to serving patient needs by working with patients at all stages of the drug development life cycle 
  • Global geographical footprint, with a presence in both established and emerging markets
  • Science driven and substantial R&D investment designed to build a high-quality and sustainable portfolio 
  • Strong capabilities from research to commercialization
  • Over 70 active global partnerships across pharma, biotech and academia